ClinicalTrials.gg
RecruitingNCT03731000Updated Mar 27, 2026

PHIL® Embolic System Pediatric IDE

An interventional study of PHIL® device in Arterio-venous Fistula and Intracranial Arteriovenous Malformations, sponsored by Alejandro Berenstein. Recruiting at 1 site in United States. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by Alejandro Berenstein · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2019; still recruiting 7 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
Up to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Arteriovenous Fistula with a site in United States — 6 open to participants now, 11 under way, none of them phase 3. Arteriovenous Fistula · United States.

Planned enrollment
37th of 45
15 · median 65
Started
2019
with 2 others
No phase
30 of 60
4 open now
Primary completion
2027-12
later than 8 of 10 live
Registered
39th of 60
by date

Among the 60 studies in Arteriovenous Fistula with a site in United States, this one is the 37th largest by planned enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2019, is one of 30 with no phase, reaches primary completion later than 8 of the 10 other live ones, and was the 39th registered.

Arteriovenous Fistula

248 studies on the registry are indexed under Arteriovenous Fistula; 44 are open to participants now.

Browse Arteriovenous Fistula studies →

Open to participants now

6 of the 60 studies in Arteriovenous Fistula with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 27 Arteriovenous Fistula studies recruiting now, 13 (48%) set no upper age limit and 4 (15%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: Up to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Arteriovenous Fistula with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to collect information about how the PHIL® Embolic System works in the treatment of intracranial dural arteriovenous fistulas. Data collected in this study will be used to evaluate the safety and probable benefits in treating DAVFs.

The PHIL® Embolic System is a Humanitarian Use Device (HUD). The U.S. Food and Drug Administration (FDA) approved the use of the PHIL Embolic System as a HUD in June 2016.

Read the detailed description

Study design:The study is a prospective, single-center, single-arm, clinical study evaluating outcomes in pediatric subjects with intracranial dural arteriovenous fistulas treated with PHIL® device.

Study purpose: To evaluate the safety and probable benefit of MicroVention, Inc. PHIL® Liquid Embolic material in the treatment of intracranial dural arteriovenous fistulas, alone or as an adjunctive treatment for dAVFs.

03

Conditions studied

  • Arterio-venous Fistula
  • Intracranial Arteriovenous Malformations

Keywords

  • Pediatric
04

Who can participate

Ages eligible
Up to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is \<22 years of age
  • Subject and legally authorized representative are willing and capable of complying with all study protocol requirements, including specified follow-up period.
  • Subject's legally authorized representative(s) must sign and date an IRB approved written prior to initiation of any study procedure
  • Subject has an intracranial dAVF that is deemed appropriate for embolization with PHIL without significantly increased risk to collateral or adjacent territories, OR subject has been previously treated with other embolic materials for dAVF.

Exclusion criteria

Exclusion Criteria:

  • Subject presents with an intracranial mass or is currently undergoing radiation therapy for carcinoma or sarcoma of the head or neck region
  • Subject has known allergies to DMSO (dimethyl sulfoxide), iodine or heparin.
  • Subject with a history of life threatening allergy to contrast media (unless treatment for allergy is tolerated).
  • Female subject is currently pregnant.
  • Subject has an acute or chronic life-threatening illness other than the neurological disease to be treated in this study including but not limited to any or debilitating disease
  • Subject has existing severe or advanced comorbid conditions which significantly increase general anesthesia and/ or surgical risk
  • Evidence of active infection at the time of treatment.
  • Subject has a history of bleeding diathesis or coagulopathy, (INR) greater than 1.5, or will refuse blood transfusions.
  • Subject weighs ≤ 2.5kg Angiographic
  • Subject has severe calcification or vascular tortuosity that may preclude the safe introduction of the sheath, guiding catheter, or access to the lesion with the microcatheter.
  • to DSA, CT scan or MRI/ MRA
  • History of intracranial vasospasm not responsive to medical therapy
  • Extra-cranial stenosis or parent vessel stenosis > 50% proximal to the target lesion to be treated.
  • Subject has a propensity to contrast induced renal injury or a potential to nephrogenic systemic fibrosis
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    PHIL® device

    Using device

    Device: PHIL® device

Interventions

  • DevicePHIL® device

    Using PHIL® device for treatment of intracranial dural arteriovenous fistulas

06

What researchers measure

Primary outcomes

  1. Proportion of participants with neurological death or major ipsilateral stroke

    The proportion of subjects with neurological death or major ipsilateral stroke (defined as a major stroke within the vascular distribution of the vessel targeted for treatment) within 12 months following completion of treatment, reported as one composite data variable

    Time frame: 12 months

  2. Proportion of participants with angiographic occlusion

    Proportion of subjects with Angiographic occlusion of the pre-specified target vessel intended for treatment at procedure following completion of treatment

    Time frame: up to 12 months

Secondary outcomes

  1. Incidence of angiographic cure

    Angiographic cure of the target dAVF, defined as complete obliteration of dAVF flow following final treatment.

    Time frame: up to 12 months

  2. Incidence of new-onset permanent morbidity

    New-onset permanent morbidity up to 12 month follow-up

    Time frame: up to 12 months

  3. Incidence of new-onset Intracranial hemorrhage (ICH)

    New-onset Intracranial hemorrhage (ICH) up to 12 month follow0up

    Time frame: up to 12 months

  4. Number of significant technical events

    Clinically significant technical events during the PHIL embolization procedure(s) including but not limited to reflux of embolic material, migration of the embolic material, catheter entrapment or damage, and vessel dissection.

    Time frame: up to 12 months

  5. Incidence of device-related adverse events at procedure

    Incidence of device-related adverse events at procedure at Day 1

    Time frame: Day 1 during procedure

  6. Incidence of device-related adverse events at 30 days

    Incidence of device-related adverse events at 30 days.

    Time frame: at 30 days

  7. Incidence of device-related mortality

    Device-related mortality at 30 days

    Time frame: at 30 days

  8. Incidence of procedure related adverse events

    Procedure related adverse events including complications of arterial puncture, contrast-induced nephropathy, renal and anesthesia-related complications.

    Time frame: up to 12 months

  9. Incidence of cranial neuropathy

    Incidence of cranial neuropathy up to 12 months follow-up

    Time frame: up to 12 months

  10. Pediatric NIH Stroke Scale (PedNIHSS)

    PedNIHSS - 11 item instrument measuring levels of impairment on a scale of 0-42 with higher score demonstrating higher levels of impairment

    Time frame: at 12 months

  11. The Pediatric Stroke Outcome Measure (PSOM)

    PSOM - measures stroke outcomes across 115 test items. On completion of the PSOM examination, the neurologist scores a Summary of Impressions containing 5 subscales: right sensorimotor, left sensorimotor (each with subcategories), language production, language comprehension, and cognitive/behavioral. Subscale scoring is 0 (no deficit), 0.5 (mild deficit, normal function), 1 (moderate deficit, decreased function), or 2 (severe deficit, missing function). The PSOM total score is the sum of the 5 subscale scores and ranges from 0 (no deficit) to 10 (maximum deficit).

    Time frame: at 12 months

  12. Number of procedures

    Number of procedures required to treat the fistula at 3-6 month follow-up

    Time frame: up to 6 months

  13. Procedure time

    Procedure time (defined as first to last fluoroscopic or digital subtraction angiographic acquisitions)

    Time frame: average of 3-4 hours

  14. Dosage of Radiation exposure

    Time frame: average of 60 minutes

  15. Radiation exposure time

    Time frame: average of 60 minutes

  16. Injected volume of PHIL

    Time frame: at time of procedure, average of 3-4 hours

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2019 (actual). Primary completion is estimated for Dec 2027, 104 months after the start.

Of 58 non-industry interventional studies with no phase under Arteriovenous Fistula, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 43. This study's planned 104 months is above that.

Counting every sponsor, half of 84 studies reached it within 21 months; a quarter within 8 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2018
First posted
Nov 5, 2018
StartActual
Apr 16, 2019
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03731000
Lead sponsor
Alejandro Berenstein
Responsible party
Alejandro Berenstein (Professor, Icahn School of Medicine at Mount Sinai) — Sponsor-investigator
First posted
Nov 5, 2018
Start date
Apr 16, 2019
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Mar 27, 2026

Study contacts

Sukaina Davdani
Contact
sukaina.davdani@mountsinai.org
(212) 241-2524
Alejandro Berenstein, MD
principal investigator · Icahn School of Medicine at Mount Sinai
Tomoyoshi Shigematsu, MD, PhD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion